









Märkte
/
Aktien
/
nasdaq-gild
/

Gilead Sciences Inc

GILD

112.290USD

-2.470-2.15%

Handelsschluss 07/31, 16:00（ET）Kurse um 15 Minuten verzögert

139.80BMarktkapitalisierung

23.44KGV TTM



Gilead Sciences Inc

112.290

-2.470-2.15%

Übersicht Unternehmen Finanzen

Finanzen

mehr Informationen über Gilead Sciences Inc Unternehmen

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.

Unternehmensinformationen

BörsenkürzelGILD

Name des UnternehmensGilead Sciences Inc

IPO-datumJan 22, 1992

Gegründet am1987

CEOMr. Daniel P. O'Day

Anzahl der mitarbeiter17600

WertpapierartOrdinary Share

GeschäftsjahresendeJan 22

Addresse333 Lakeside Dr

StadtFOSTER CITY

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl94404-1147

Telefon16505743000

Websitehttps://www.gilead.com/

BörsenkürzelGILD

IPO-datumJan 22, 1992

Gegründet am1987

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Ms. Johanna Mercier

Chief Commercial Officer

89.94K

-3.23%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

25.70K

+23.67%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

Mr. Andrew D. (Andy) Dickinson

Chief Financial Officer

Mr. Harish Manwani

Independent Director

Dr. Ted W. Love, M.D.

Independent Director

Mr. Javier J. Rodriguez

Independent Director

Name

Name/Position

Position

Aktienbesitz

Veränderung

Ms. Johanna Mercier

Chief Commercial Officer

89.94K

-3.23%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

25.70K

+23.67%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

Umsatzaufteilung

Währung: USDAktualisiert: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Biktarvy

3.15B

47.25%

Descovy

586.00M

8.79%

Yescarta

386.00M

5.79%

Genvoya

364.00M

5.46%

Sofosbuvir/Velpatasvir

345.00M

5.17%

Other

1.84B

27.54%

Nach RegionUSD

Name

Umsatz

Anteil

United States

4.47B

67.02%

Europe

1.06B

15.94%

Other Locations

829.00M

12.43%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Biktarvy

3.15B

47.25%

Descovy

586.00M

8.79%

Yescarta

386.00M

5.79%

Genvoya

364.00M

5.46%

Sofosbuvir/Velpatasvir

345.00M

5.17%

Other

1.84B

27.54%

Aktionärsstatistik

Aktualisiert: Thu, May 15

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

9.40%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Capital Research Global Investors

4.39%

Capital World Investors

4.30%

Other

71.44%

Aktionäre

Anteil

The Vanguard Group, Inc.

9.40%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Capital Research Global Investors

4.39%

Capital World Investors

4.30%

Other

71.44%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

52.90%

Investment Advisor/Hedge Fund

25.33%

Research Firm

2.92%

Pension Fund

2.92%

Hedge Fund

2.04%

Bank and Trust

1.84%

Sovereign Wealth Fund

1.72%

Insurance Company

0.13%

Individual Investor

0.08%

Other

10.11%

Institutionelle Beteiligung

Aktualisiert: Tue, Jul 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q2

3373

1.12B

90.10%

-7.74M

2025Q1

3442

1.12B

90.14%

-10.49M

2024Q4

3313

1.12B

90.13%

+4.63M

2024Q3

3207

1.10B

88.48%

-11.56M

2024Q2

3188

1.10B

88.24%

-14.37M

2024Q1

3196

1.10B

88.13%

-22.04M

2023Q4

3252

1.11B

88.75%

-8.79M

2023Q3

3190

1.10B

88.14%

-23.58M

2023Q2

3196

1.10B

88.02%

-11.22M

2023Q1

3195

1.09B

87.26%

-11.17M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

116.91M

9.4%

+1.94M

+1.69%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

70.66M

5.68%

-3.80M

-5.11%

Mar 31, 2025

State Street Global Advisors (US)

59.52M

4.79%

-858.08K

-1.42%

Mar 31, 2025

Capital Research Global Investors

54.61M

4.39%

-3.34M

-5.76%

Mar 31, 2025

Capital World Investors

53.55M

4.3%

-18.16M

-25.32%

Mar 31, 2025

Fidelity Management & Research Company LLC

51.21M

4.12%

+16.57M

+47.83%

Mar 31, 2025

Dodge & Cox

32.69M

2.63%

-252.93K

-0.77%

Mar 31, 2025

Geode Capital Management, L.L.C.

28.48M

2.29%

+190.23K

+0.67%

Mar 31, 2025

Wellington Management Company, LLP

27.36M

2.2%

-8.30M

-23.28%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

25.70M

2.07%

-130.67K

-0.51%

Jun 30, 2025

Verbundene ETFs

Aktualisiert: Sun, Jul 6

Name

Anteil

VanEck Biotech ETF

13.56%

Invesco Nasdaq Biotechnology ETF

8.68%

ProShares Ultra Nasdaq Biotechnology

7.94%

iShares Biotechnology ETF

7.81%

Coastal Compass 100 ETF

5.83%

Invesco Pharmaceuticals ETF

5.41%

Invesco Biotechnology & Genome ETF

5.25%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

4.41%

USCF Dividend Income Fund

4.27%

First Trust NASDAQ Pharmaceuticals ETF

3.9%

VanEck Biotech ETF

Anteil13.56%

Invesco Nasdaq Biotechnology ETF

Anteil8.68%

ProShares Ultra Nasdaq Biotechnology

Anteil7.94%

iShares Biotechnology ETF

Anteil7.81%

Coastal Compass 100 ETF

Anteil5.83%

Invesco Pharmaceuticals ETF

Anteil5.41%

Invesco Biotechnology & Genome ETF

Anteil5.25%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

Anteil4.41%

USCF Dividend Income Fund

Anteil4.27%

First Trust NASDAQ Pharmaceuticals ETF

Anteil3.9%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 18.49B USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Feb 11, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025

Mar 14, 2025

Mar 28, 2025

Mar 14, 2025

Nov 12, 2024

GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024

Dec 13, 2024

Dec 30, 2024

Dec 13, 2024

Aug 13, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024

Sep 13, 2024

Sep 27, 2024

Sep 13, 2024

Apr 26, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024

Jun 14, 2024

Jun 27, 2024

Jun 14, 2024

Feb 06, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Mar 28, 2024

Mar 14, 2024

Nov 08, 2023

GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023

Dec 15, 2023

Dec 28, 2023

Dec 14, 2023

Aug 07, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Sep 28, 2023

Sep 14, 2023

Apr 28, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jun 29, 2023

Jun 14, 2023

Feb 02, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Mar 30, 2023

Mar 14, 2023

Oct 27, 2022

GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022

Dec 15, 2022

Dec 29, 2022

Dec 14, 2022

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

KeyAI

